The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Biosimilars MORE >>

Filgrastim-aafi, a filgrastim biosimilar, has been approved by the FDA to treat side effects associated with cancer treatment, including febrile neutropenia and severe neutropenia, according to an announcement from Pfizer, the manufacturer of the biosimilar.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.